Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now I know IGPK is getting ready for a big run up, whenever the Whale surfaces, it's time to hold tight and enjoy the ride up.
Come on now, lock in that$0.008.
How many years till IGPK reaches $0.25? IMHO, this should be trading between $0.22-$0.25 now...
I look forward to the day when IGPK moves up $0.01+ a day.
I'd like to see IGPK close @ $0.0055, however I'll settle for 0.005
I 'm not greedy, I'd be happy with $0.45 a share. Anyone has a good guess as to when we can reach that. TIA...
I would guess, because the Audited Fianacial's are due sometime this month.
It's a case of show me the proof (money)...
I just picked up another nice block @ 0.0031, it pays off to keep that super low bid in, you just never know when it will drop and fill. GLTA
I will hang around till November, as per the CEO stating that the name/ticker change should take another 2 months. in addition, the CEO stated they will have audited financials with in 2 months. I will stick around that long, however after that time period, I'll have to rethink what I'm going to do here. GLTA
LoL, keep the time difference in mind, by the time the interview started, it was already Monday morning in China.
Here's my 2 cents, keeping the last interview in mind... IGPK rose up nicely within the first hour and a half the next morning, then it took a downturn, or shall I say the flippers came in and took IGPK down. IMHO I think the same thing will happen again. On another note, there is that gap at 0.0047 to keep in mind. I for one am happy with the shares I have and will not be chasing at this time, however if it goes below the GAP, I'll be buying. GLTA...
Here's a tip when using X, every time you want to post about IGPK, use #IGPK & $IGPK within your post, everyone that is interested in IGPK will then see your post.
Yes, it was that day, the day the R/S bull/sh-t came out.
I was able to get 2 blocks @ 0.0025 this past March 19th.
Oh sweetie, you just need to know when to pick-up your shares... my bids have been set at 0.0025, 0.0030 & 0.0035... I've been very successful keeping a low bid in place. I don't know when it's going to happen, however it does happen. GLTY
I see it going to 0.0030 before the interview.
Point taken, however this is not going to happen overnight & I do see this as being a 3–4-year investment, sorry to say.
I find that interesting, a week -a week & half ago, the CEO said we will be rolling all divisions in at one time for a tax break, he did not give a set time for this being done. I'm sure I saw this post on this board. If not, here it was posted here from Twitter/X.
Just ignore HER/him, it was already posted that they are here to flip for a fraction or a cent, this is the type of person that will keep the PPS down.
Something has awoken sleeping beauty, MCET is up 19,900.00% today on no news.
Well, I'll keep my bid in for 0.0025, I think we'll see 0.0025 this week.
Well, it pays off to keep a low bid in, I picked up another nice block @0.003 today.
I look at it as dollar cost averaging.
With the last fake R/S pump & dump, I was able to Sanch 2 nice blocks @ 0.0025. I try to keep a low bin in all the time, you just never know when it will happen, however it does from time to time. Diamond hands here
On Sunday I placed a bid offer @ 0.003 & 0.0025 well I just might get 0.003 today. Fingers crossed
That's a good 3 weeks away, most likely the day before the Q2 drops. I don't see any anticipation buying till then.
I'm not sure, it was just a thought.
If I were a betting man, I would say that when the company had to change the ticker/name back to IGPK meant that the company had to reapply and start from scratch and get back in line... so I would say you are looking at a 3–6-month time period from the date they went back to IGPK. This is JMO.
JMO... Name/ticker change can't happen until all divisions are rolled into IGPK/JFHE... That was the problem the last time the ticker changed. JFHE will not be able to upload any quarterly financials until JFHE shows 100% of the companies worth.
I seem to be missing something, CC&C don't owe anything to ENZC (share holders). They were paid off by SAGA... it's done. CC&C took all of their patents, AI and IP's and moved on. It's time to wake up and smell the coffee, we were all had, I lost (I haven't sold yet, so not yet a loss) over $314,000.00 & I'll never be able to make that back up with ENZC.
LoL, I'll Show you one... I found PLPL over a year ago and it is the only OTC stock that I'm green in... not much green, but it's green.
My guess is that your broker is in the process of paying out your dividend. My account on the other hand shows nothing, no change at all.
Once my accounts are credited, I'll have 4136 RGBPP shares between both accounts.
Well, I haven't received mine yet and I've been holding since 2021, it could be because all of me shares are in 2 of my E*TRADE's accounts.
This was copied from stocktwits.
$RGBP
RGBP
Regen Biopharma Inc
Good morning! I spoke with both my Fidelity and Schwab brokerage accounts again this morning to verify that they can now see that the preferred share dividend is pending with today being the pay date and Friday the 5th being the effective ex-dividend date according to FINRA, and they both acknowledged that they are seeing the dividend on their end now and that I qualify for the record date, and I should see the RGBPP shares delivered into my accounts by Friday. Have a great day everyone!
This won't run till the name change goes into effect, and or the next CEO Interview, time will tell. I'm hopeful.
I'm not sure what's going on here, I've been holding since mid Sept 2021. One would think that the TICKER/NAME change would have happened long before now. I'm beginning to think that the KOK plaything may have messed everything up for this company.
RGBPP is up 0.25 today @ $1.75
Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment
Press Release | 07/01/2024
Update on Sagaliam Acquisition Corp.
ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company is entering into a worldwide exclusive licensing agreement for US Patent # 8067531-B2, "Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells," applying Immunotherapy Treatment to the global fight against cancer. ENZC continues to explore therapeutic applications of the patent, and is preparing to commence Federal Drug Administration ("FDA") in-vitro studies. ENZC has developed a Statement of Work with a major university in Texas to further this effort.
In the interim, the Company will pursue various regulatory paths under "Right to Try Laws" for application to terminally ill stage four cancer patients. This could be achieved by approval of an individual IND to help prolong lives. Immune treatment, such as ITP-immune therapeutic protein, does not substitute for existing chemo therapy treatments.
Additionally, Dr. Lachezar Ivanov, Director of ENZC and member of the Bulgarian Senate, is negotiating the acquisition of a pharmaceutical manufacturing facility in Bulgaria which meets the Good Manufacturing Process ("GMP") standard required by the European Medicine Association ("EMA"). The manufacturing facility will be an integral part of the ENZC portfolio of products for the nutraceutical market as well as the manufacturing and distribution of its other licensed immunotherapy treatments.
Sagaliam Acquisition Corp. ("SAGA") has provided the Company with an update on multiple efforts including its application with OTC Markets. Currently, SAGA has secured funding for completion of the necessary audits required for the next steps toward completion of its application for membership on the OTC board and has engaged a PCAOB auditor.
Operationally, SAGA has filed two new patent applications, one for its Multiple Sclerosis immunotherapy treatment, for which a provisional application was previously filed, and the other for the Peptide Complex modulation of the immune system. A worldwide license will be awarded by the patent owner for both treatments to SAGA. Progress is being made to move forward with clinical trials in Europe to assess the effects of ITV-1 on diabetic patients. Additionally, progress continues to be made on the permitting of ITV-1 for treatment of HIV/Aids with the EMA.
SAGA and ENZC are coordinating the dividend approval process of the shares issued in association with the sale by ENZC of Virogentics, Inc. to SAGA in September of last year. The make-whole provision will apply to all shares distributed to ENZC shareholders.
Harry Zhabilov, Chief Science Officer of ENZC and SAGA, stated, "Enzolytics' licensing of the Cancer immunotherapy treatment is an expansion of its cutting edge portfolio of technology IP and products. The continued growth of the product base of the Company and Saga will give us the opportunity to utilize the skills, experience and expertise of our management team and partners."
Steve Sharabura, the CEO of Enzolytics commented, "In addition to the exciting progress on intellectual property, we will continue to build a robust IP portfolio going forward. We are also enthusiastic about moving forward on our ETC Marketing initiative, with an initial focus on consumer sales of nutraceutical products. With the current explosion of online communities, we appreciate the value of digital marketing and the power of social media augmented by AI. As we expand our consumer engagement through ETC Marketing, we will also use these tools to increase engagement with our investors and expand awareness and education related to our well-being therapies."
Barry Kostiner, the CEO of Sagaliam commented, "We are looking forward to regaining compliance and getting SAGA listed on OTC. Historically, Enzolytics' valuation has exceeded $500M, reflecting the value of the ITV-1 intellectual property embedded in Virogentics. Once the SAGA OTC listing is in place, we will be able to issue the dividend of SAGA shares to Enzolytics, and complete the funding needed to move forward on clinical trials and bring ITV-1 to market. Our technology has been well established, and we have only a few regulatory steps needed to bring value to SAGA and ENZC shareholders and make significant contributions to global health. The application to HIV in Europe and Africa will be well on its way within 6 months of completing the SAGA OTC listing, and work on applications to diabetes and cancer would commence within another 6 months.
About Enzolytics, Inc.
Enzolytics, Inc. is transitioning from a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases to a sales, marketing and distribution entity focusing on medical devices, medical testing and nutraceutical products.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Enzolytics, Inc.
Steve Sharabura, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
X/Twitter: @EnzolyticsInc
SOURCE: Enzolytics, Inc.
View the original press release on accesswire.com
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Verified Profile IconVerified Profile 04/2024
Transfer Agent Verified IconTransfer Agent Verified
DAILY ADVANCERS
OTCQX Best Market Logo
NVLPF
+ 54.55 %
OTCQX Best Market Logo
TTNMF
+ 53.15 %
OTCQX Best Market Logo
TAKOF
+ 21.33 %
OTCQX Best Market Logo
YERBF
+ 14.81 %
OTCQX Best Market Logo
AONC
+ 12.38 %
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Enter your email